1/31/14 Contest update
For the S&P 500, it was the first January loss since 2010. But despite a bit of harassment by the Bears, biotechs managed to finish the month in positive territory. At Friday’s close, the Contest median was up 16.10% YTD (vs. up 17.54% YTD a week ago), while the Nasdaq Biotech Index actually held its ground, finishing the week up 8.41% YTD (vs. up 7.64% YTD a week ago). However, the Nasdaq Composite Index closed down -1.74% YTD (vs. down -1.16% YTD a week ago).
Although my own portfolio did get clawed back, it still held the Contest lead with 44.75% YTD gain. JB118’s portfolio, up 30.79% YTD, took second place, with ROCKY's portfolio, up 30.66% YTD, behind by a hair in third place.
At Friday's close, all 46 Contest portfolios continued in the black but a mere 39 of the 46 were now beating the NBI.
Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week.
Portfolio adjustments: none
(All corrections, especially adjustments for splits, greatly appreciated.)
Have a concussion-free Super Bowl weekend biotechies!
Peace & good health,
Bulba
1/31/14
Rank Name Profit/Loss
1 BULBA 44,747
2 JB118 30,785
3 ROCKY 30,658
4 BIOINV 29,762
5 GUERL 28,809
6 ROBERT 27,664
7 GENE 26,928
8 SCARAM 26,475
9 DOUGH 25,581
10 MCBIO 23,658
Week's Top 5 Gainers
Symbol 1/17 1/31 Wk.%chg.
ARWR 11.72 15.34 30.89%
PRAN 8.99 11.60 29.03%
ENTA 30.03 36.58 21.81%
MRNA 0.74 0.89 21.09%
PRTA 25.95 30.94 19.23%
Week's Worst 5 Losers
Symbol 1/17 1/31 Wk.%chg.
KBIO 5.32 3.120 -41.35%
PGNX 6.37 4.780 -24.96%
ITMN 16.85 13.350 -20.77%
FPRX 18.46 14.660 -20.59%
CTIC 4.00 3.190 -20.25% |
